Global Influenza Vaccine Market 2018-2022: Trends, Drivers & Challenges - Market to Grow at a CAGR of 7.23%
DUBLIN, Jan. 15, 2018 /PRNewswire/ --
The "Global Influenza Vaccine Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global influenza vaccine market to grow at a CAGR of 7.23% during the period 2018-2022.
Global Influenza Vaccine Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of influenza vaccine.
The market encompasses both live attenuated as well as recombinant influenza vaccines for the prevention of influenza. The major factors that lead to the market growth include the need for annual vaccination and government initiatives to improve awareness about vaccination.
The latest trend gaining momentum in the market is development of strong pipeline. The increasing R&D programs is significantly influencing the growth of the pipeline molecule count in the influenza market. Universal influenza vaccine initiative (UIVI) is a program conducted to combat the challenges in developing a vaccine that broadly protects against all types of influenza viruses.
Furthermore, the number of clinical trials for developing a vaccvine for treating influenza is steadily increasing. The launch of all molecules in phase III will generate significant revenue on completion of the clinical trials.
According to the report, one of the major drivers for this market is rising awareness about influenza vaccination. With the growing support of both government and non-government bodies, the awareness about influenza virus is rising across the globe. Both the government and non-government organizations are taking adequate initiatives to prevent diseases.
To educate people about the influenza virus and the importance of influenza vaccination, CDC conducts national vaccination week. WHO has developed generic campaign materials to support the campaign. Such initiatives will help people gain more knowledge about the preventive measures available against influenza, in turn, driving the demand for these vaccines.
Key vendors
- AstraZeneca
- CSL
- GlaxoSmithKline
- Sanofi
Other prominent vendors
- Altimmune
- BionVax
- FluGen
- FOLIA BIOTECH
- Genentech
- Green Cross
- Medicago
- Moderna Therapeutics
- Novavax
- Shijiazhuang Yiling Pharmaceutical
- SK Chemicals
- UNM Pharma
- Vaccitech
- Vaxart
- Vaxine Pty
- Visterra.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MARKET LANDSCAPE
PART 06: MARKET SIZING
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
- Overview
- Comparison by vaccine type
- Global live attenuated influenza vaccines market
- Global recombinant influenza vaccines market
- Market opportunity by vaccine type
PART 10: MARKET SEGMENTATION BY AGE GROUP
- Adults
- Pediatrics
PART 11: CUSTOMER LANDSCAPE
PART 12: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Market opportunity
PART 13: DECISION FRAMEWORK
PART 14: DRIVERS AND CHALLENGES
PART 15: MARKET TRENDS
- Strong pipeline
- Strategic alliances
PART 16: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 17: VENDOR ANALYSIS
PART 18: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/fnss56/global_influenza?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article